{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-296619","form_type":"8-K","ticker":"RPRX","cik":"0001802768","company_name":"Royalty Pharma plc","filed_at":"2022-12-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.202881+00:00","generated_at":"2026-06-21T11:06:01.183511+00:00","sec_items":["2.06"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Royalty Pharma records $273.6M impairment on gantenerumab royalty after Roche halts trials","bullets":["Non-cash impairment charge of $273.6M related to gantenerumab financial royalty asset.","Roche discontinued gantenerumab trials Nov 30, 2022 after GRADUATE I/II missed primary endpoint.","Impairment reflects entire net carrying value as of Sept 30, 2022; no impact on non-GAAP results.","No portion of the charge relates to future cash expenditures.","Charge will be recorded in Q4 2022 under GAAP."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-296619","json":"https://secwatch.observer/filing/0001193125-22-296619.json","markdown":"https://secwatch.observer/filing/0001193125-22-296619.md","text":"https://secwatch.observer/filing/0001193125-22-296619.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/0001193125-22-296619-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/d432184d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T11:06:01.183511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"fb74e71b537f58522ef82de8c861de2c2440dec9","claim":"Royalty Pharma plc announced a impairment with charges of $273.6 million affecting financial royalty asset associated with gantenerumab.","evidence_excerpt":"endpoint of slowing clinical decline, which led the Company to conclude its financial royalty asset is impaired. The Company expects that the non-cash impairment charge will be $273.6 million, which was the net carrying value of the asset as of September 30, 2022. No portion of the impairment charge relates to future cash expenditures. SIGNATURES Pursuant to the","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802768/000119312522296619/0001193125-22-296619-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"impairment"},{"label":"Charge","value":"$273.6 million"},{"label":"Affected area","value":"financial royalty asset associated with gantenerumab"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}